Nepean, Canada Clinical Trials

A listing of Nepean, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 190 clinical trials
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

This 110-week study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

eczema
atopy
hormonal contraception
topical agents
progestogen
Dermatology Ottawa Research Centre
 (2.4 away) Contact site
  • 626 views
  • 28 Oct, 2022
  • +257 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To determine fitusiran plasma concentrations at selected time points

Investigational Site Number :1240002
 (5.7 away) Contact site
  • 4 views
  • 02 Dec, 2022
  • +5 other locations
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed)

Primary Objective: To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: To evaluate the efficacy of BIVV001 as a prophylaxis treatment. To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. To evaluate BIVV001 consumption for prevention and treatment of bleeding …

Investigational Site Number :1240002
 (5.7 away) Contact site
  • 0 views
  • 26 Jan, 2023
  • +63 other locations
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

This is a Phase 2, randomized, double-blind, placebo-controlled 2 parallel-arm study to assess the effect on serum neurofilament light chain (sNfL), safety and tolerability of oral SAR443820 compared to placebo in male and female participants aged 18 to 60 years with relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) …

secondary progressive multiple sclerosis
body mass index
teriflunomide
glatiramer acetate
disease or disorder
Investigational Site Number :1240001
 (7.5 away) Contact site
  • 0 views
  • 03 Feb, 2023
  • +15 other locations
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation). It is also to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination …

pembrolizumab
nivolumab
BRAF
advanced melanoma
ipilimumab
Local Institution - 0044
 (5.9 away) Contact site
  • 3 views
  • 15 Oct, 2022
  • +7 other locations
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop …

The Ottawa Hospital
 (4.0 away) Contact site
  • 0 views
  • 16 Oct, 2022
  • 1 location
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial) (ARGUS)

The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in children and adult participants with Dravet Syndrome.

clemizole hydrochloride
convulsive seizures
tonic
antiepileptic
adjunctive therapy
Children's Hospital of Eastern Ontario
 (5.8 away) Contact site
  • 63 views
  • 17 Oct, 2022
  • +10 other locations
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology: A Multicenter Randomized Controlled Trial

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone. This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same …

osteotomy
hip arthroscopy
arthroscopy
Ottawa Hospital Research Institute
 (5.8 away) Contact site
  • 1 views
  • 16 Oct, 2022
  • +6 other locations
A Randomized, Double-blind Controlled Trial Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement for the Management of Chronic Lateral Epicondylitis

We propose a randomized, double-blind controlled trial comparing arthroscopic release with arthroscopic debridement for the management of chronic tennis elbow in an effort to definitively determine whether arthroscopic tennis elbow release is an effective treatment of tennis elbow, and to further provide better recommendations for the use of this procedure, …

conservative management
The Ottawa Hospital, General Campus
 (6.1 away) Contact site
  • 76 views
  • 18 Oct, 2022
  • 1 location
REmote Cardiac MOnitoring of At-risk SYNCope Patients After Emergency Department Discharge - A Multicenter Randomized Controlled Trial: REMOSYNCED (REMOSYNCED)

Syncope (fainting) is a common reason for emergency department (ED) presentation. Fainting can be caused by heart conditions such as irregular heart rhythm (arrhythmia) that can be life-threatening, structural heart problems, or serious conditions not related to the heart. The standard or usual treatment for the majority of patients at-risk …

The Ottawa Hospital - Civic and General Campuses
 (4.0 away) Contact site
  • 0 views
  • 24 Oct, 2022
  • 1 location